Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.
The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...
By Gina Kolata The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 percent of their weight in a year. The drug, MariTide ...
Newsweek on MSN14d
Amgen Obesity Drug More Effective Than CompetitorsA new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.
Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of people who ...
The discontinuation of STRIDES is a rare stumble for the next-generation obesity field and comes just weeks after Amgen ...
Amgen’s drug, maridebart cafraglutide, or MariTide, was tested with doses administered monthly or even less frequently. In the consumer-driven obesity drug market, some analysts say comparable ...
The drug, MariTide, also helped patients with obesity and Type 2 diabetes lose up to 17% of their weight after a year. The company said it did not observe a plateau in either group of patients ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback